Right of Assignment

In insurance, the right of assignment refers to the policy owner's ability to transfer their ownership rights in the policy to another individual or entity. This allows the policy owner to sell, gift, or assign their policy to another party, who then becomes the new owner of the policy and assumes all the rights and obligations that come with it.

Some key features of the right of assignment in insurance include:

  • Transferability: The policy owner has the right to transfer ownership of the policy to another party.

  • Irrevocability: Once the assignment is made, it cannot be revoked by the policy owner.

  • Consent: The insurer typically requires the consent of the policy owner and the new owner before the assignment is valid.

  • Documentation: The assignment must be documented in writing and submitted to the insurer.

  • Assignee's rights: The new owner assumes all the rights and obligations of the policy, including the right to receive the policy benefits and the obligation to pay premiums.

For example, suppose John owns a life insurance policy and wants to transfer ownership of the policy to his daughter, Jane. John can exercise his right of assignment by completing the necessary paperwork and submitting it to the insurer. Once the assignment is complete, Jane becomes the new owner of the policy and assumes all the rights and obligations that come with it, including the right to receive the death benefit and the obligation to pay premiums.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.